Press Releases

 
Press Releases
  Date Title and Summary View
Oct 22, 2014
REDWOOD CITY, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market Patiromer for Oral Suspension (Patiromer FOS) for the treatment of hyperkalemia, a serious condition defined as abn...
Oct 16, 2014
REDWOOD CITY, Calif., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on October 15, 2014, the compensation committee of the company's board of directors granted ten new employees options to purchase an aggregate of 146,000 shares of the company's common stock with a per share exercis...
Sep 30, 2014
REDWOOD CITY, Calif., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview at the 13th Annual BIO Investor Forum on October 7, 2014 at 2:30 p.m. PT. To access the live webcasts and subsequent archived recording...
Sep 18, 2014
REDWOOD CITY, Calif., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview at the Newsmakers in the Biotech Industry Conference on September 26, 2014 at 9:30 a.m. ET. To access the live webcasts and subsequent ...
Sep 16, 2014
REDWOOD CITY, Calif., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on September 15, 2014, the compensation committee of the company's board of directors granted seven new employees options to purchase an aggregate of 63,500 shares of the company's common stock with a per share exe...
Sep 15, 2014
REDWOOD CITY, Calif., Sept. 15, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data in heart failure (HF) patients from its pivotal Phase 3 clinical trial of patiromer, the company's lead product candidate, were presented as a late-breaking oral presentation at the 18th Annual Scientific Meet...
Sep 9, 2014
REDWOOD CITY, Calif., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that it has entered into a multi-year commercial manufacturing and supply agreement with Patheon, Inc. for finished product manufacture of patiromer, Relypsa's novel polymer in development for the treatment of hyperkalem...
Sep 8, 2014
REDWOOD CITY, Calif., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from its pivotal Phase 3 clinical trial of patiromer, the company's lead product candidate, will be presented as a late-breaking oral presentation at the 18th Annual Scientific Meeting for the Heart Failure Soc...
Sep 3, 2014
REDWOOD CITY, Calif., Sept. 3, 2014 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Relypsa, Inc. (Nasdaq:RLYP), please note that the conference time listed in the first paragraph should be 3:30 p.m. ET, not 2:55 p.m. ET as originally issued. The corrected text follows: Relypsa, Inc. (Nasdaq:RLYP), a biophar...
Aug 11, 2014
REDWOOD CITY, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2014. Net loss for the second quarter 2014 was $16.7 million, or $0.51 per share, compared to $20.2 million, or $64.87 per share, for the comparable period in 2013. ...
Page:
1
... NextLast
= add release to Briefcase